AUS
NZ
UK
CA
USA
IND
In a significant move set to reshape the landscape of healthcare distribution in China, 111, Inc. (NASDAQ: YI) and Beijing Scrianen Pharmaceutical Co., Ltd. (Scrianen) have joined forces in a strategic direct supply partnership. The announcement, made public recently, marks a pivotal moment for both companies as they aim to digitally empower the healthcare industry's value chain, particularly in the realm of pharmaceutical distribution.
The signing ceremony of the partnership, attended by key figures including Dr. Gang Yu, co-founder and executive chairman of 111, and Bin Yi, chairman of Scrianen, underscores the gravity of this collaboration. With senior management teams from both entities present, the occasion symbolizes a commitment to enhancing their existing collaboration and propelling it to new heights.
Since 2017, 111 has been an integral part of Scrianen's Authentic Alliance, laying the groundwork for this latest endeavor. The Partnership represents a strategic evolution of their relationship, with a renewed focus on leveraging advanced technologies such as big data analytics, digital marketing, and cloud services. Together, they aim to optimize the distribution channels for Scrianen's products, with a spotlight on "Scrianen Folic Acid Tablets" for nationwide distribution.
At the core of this collaboration lies a shared vision of expanding accessibility to high-quality healthcare products across China. By harnessing 111's integrated online and offline healthcare ecosystem, which includes the acclaimed "1 Pharmacy" online retail platform, self-operated offline pharmacies, online doctor-patient management services, digital pharmaceutical distribution services, and a robust SaaS-based "1 Health Membership program," the partners aspire to reach a broader audience with unprecedented efficiency.
Scrianen, a trailblazer in the pharmaceutical landscape, brings to the table a rich portfolio spanning reproductive health, maternal and child health, orthopedics, oncology, gynecology, pediatrics, and geriatric diseases. Notably, their flagship product, "Scrianen Folic Acid Tablets," holds the distinction of being the first 0.4mg folic acid tablet to receive new drug certification and production approval from the National Health Commission in 1997. Recognized by the World Health Organization for its exemplary quality standards, it has earned a place in the esteemed Chinese Pharmacopoeia.
The strategic alignment between 111 and Scrianen signifies more than just a business partnership; it heralds a paradigm shift in healthcare distribution dynamics. By synergizing their respective strengths and resources, both companies are poised to unlock new avenues for growth and innovation in the healthcare sector. With a shared commitment to excellence and a relentless pursuit of customer-centric solutions, they are poised to redefine the standards of healthcare delivery in China.
As the healthcare landscape continues to evolve, collaborations like the one between 111 and Scrianen serve as a beacon of hope, demonstrating the transformative power of strategic partnerships in driving progress and fostering a healthier, more equitable future for all.
